{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:01:20Z","timestamp":1791486080278,"version":"4.3.4"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T00:00:00Z","timestamp":1300147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0017733","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T19:05:03Z","timestamp":1300302303000},"page":"e17733","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":93,"title":["Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer"],"prefix":"10.1371","volume":"6","author":[{"given":"Mahavir B.","family":"Chougule","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanise","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandip","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.","volume":"9","author":"F Kassam","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","article-title":"What is triple-negative breast cancer?","volume":"44","author":"WJ Irvin Jr","year":"2008","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/CCO.0b013e328312efba","article-title":"Triple-negative breast cancer.","volume":"20","author":"G Stockmans","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.clpt.6100449","article-title":"Advances in the treatment of breast cancer.","volume":"83","author":"S Moulder","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1634\/theoncologist.8-4-335","article-title":"Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.","volume":"8","author":"AU Buzdar","year":"2003","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer.","volume":"109","author":"EA Rakha","year":"2007","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1158\/1535-7163.MCT-06-0205","article-title":"Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice.","volume":"5","author":"R Aneja","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.","volume":"8","author":"EA Perez","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1010618632738","article-title":"Role of formulation vehicles in taxane pharmacology.","volume":"19","author":"L van Zuylen","year":"2001","journal-title":"Invest New Drugs"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00520-002-0405-9","article-title":"Managing taxane toxicities.","volume":"11","author":"M Markman","year":"2003","journal-title":"Support Care Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1021\/jm050674q","article-title":"Identification of novel and improved antimitotic agents derived from noscapine.","volume":"48","author":"JT Anderson","year":"2005","journal-title":"J Med Chem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1021\/jm0494220","article-title":"Discovery of S-phase arresting agents derived from noscapine.","volume":"48","author":"JT Anderson","year":"2005","journal-title":"J Med Chem"},{"key":"ref13","first-page":"4109","article-title":"Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma.","volume":"62","author":"JW Landen","year":"2002","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"39777","DOI":"10.1074\/jbc.M203927200","article-title":"Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine.","volume":"277","author":"J Zhou","year":"2002","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2005-08-3516","article-title":"Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011.","volume":"107","author":"R Aneja","year":"2006","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/CAD.0b013e3282eea257","article-title":"Apoptotic pathway induced by noscapine in human myelogenous leukemic cells.","volume":"18","author":"N Heidari","year":"2007","journal-title":"Anticancer Drugs"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-04-0360","article-title":"Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.","volume":"10","author":"JW Landen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00280-008-0720-z","article-title":"Antitumor activity of noscapine in human non-small cell lung cancer xenograft model.","volume":"63","author":"T Jackson","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1073\/pnas.95.4.1601","article-title":"Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.","volume":"95","author":"K Ye","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1158\/0008-5472.CAN-05-2962","article-title":"Rational design of the microtubule-targeting anti-breast cancer drug EM015.","volume":"66","author":"R Aneja","year":"2006","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-010-0106-1","article-title":"Clinicopathological features and treatment strategy for triple-negative breast cancer.","author":"Y Yamamoto","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2407-7-203","article-title":"Prognostic impact of clinicopathologic parameters in stage II\/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.","volume":"7","author":"B Keam","year":"2007","journal-title":"BMC Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0360-3016(99)00127-3","article-title":"Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer.","volume":"45","author":"PH Hardenbergh","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2010.02.006","article-title":"Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.","volume":"144","author":"RR Patlolla","year":"2010","journal-title":"J Control Release"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-08-1558","article-title":"Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer.","volume":"15","author":"N Ichite","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","article-title":"Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.","volume":"10","author":"L Zhao","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref27","article-title":"Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer.","author":"M Chougule","year":"2010","journal-title":"Lung Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1080\/10428190802213480","article-title":"Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro.","volume":"49","author":"L Hiser","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2010.01.001","article-title":"Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.","volume":"293","author":"SJ Wang","year":"2010","journal-title":"Cancer Lett"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijrobp.2008.04.020","article-title":"Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.","volume":"71","author":"EW Newcomb","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00280-007-0430-y","article-title":"Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.","volume":"60","author":"R Aneja","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF00609627","article-title":"Pharmacokinetic properties of noscapine.","volume":"22","author":"B Dahlstrom","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.","volume":"100","author":"PD Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/0008-5472.CAN-05-3963","article-title":"Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice.","volume":"66","author":"A Ewens","year":"2006","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e10365","DOI":"10.1371\/journal.pone.0010365","article-title":"Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.","volume":"5","author":"A Bandyopadhyay","year":"2010","journal-title":"PLoS One"},{"key":"ref36","first-page":"617","article-title":"Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.","volume":"2","author":"Q Pan","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/intimm\/13.12.1479","article-title":"NF-kappa B activation plays an important role in the IL-4-induced protection from apoptosis.","volume":"13","author":"J Zamorano","year":"2001","journal-title":"Int Immunol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/0008-5472.CAN-09-4230","article-title":"Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway.","volume":"70","author":"B Sung","year":"2010","journal-title":"Cancer Res"},{"key":"ref39","article-title":"Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo.","author":"M Liu","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref40","first-page":"3701","article-title":"Noscapine inhibits human prostate cancer progression and metastasis in a mouse model.","volume":"28","author":"I Barken","year":"2008","journal-title":"Anticancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/157489209787002524","article-title":"The anti-cancer activity of noscapine: a review.","volume":"4","author":"M Mahmoudian","year":"2009","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/0008-5472.CAN-06-4282","article-title":"p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells.","volume":"67","author":"R Aneja","year":"2007","journal-title":"Cancer Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0959-8049(00)00408-1","article-title":"Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells.","volume":"37","author":"JA Menendez","year":"2001","journal-title":"Eur J Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO;2-E","article-title":"Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis.","volume":"91","author":"H Kawasaki","year":"2001","journal-title":"Cancer"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1476-4598-8-93","article-title":"EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells.","volume":"8","author":"P Karna","year":"2009","journal-title":"Mol Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0017733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T10:54:47Z","timestamp":1592391287000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0017733"}},"subtitle":[],"editor":[{"given":"Irina","family":"Agoulnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,3,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0017733","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,15]]}}}